These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23514013)

  • 21. Assessing new therapies and their overall impact in myelofibrosis.
    Mesa RA
    Hematology Am Soc Hematol Educ Program; 2010; 2010():115-21. PubMed ID: 21239780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
    Barba P; Fox ML; Blanco A; Valcárcel D
    Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
    [No Abstract]   [Full Text] [Related]  

  • 24. [Primary myelofibrosis--pathogenesis, diagnosis and treatment].
    Ghanima W; Knutsen H; Delabie J; Bruserud Ø
    Tidsskr Nor Laegeforen; 2013 Oct; 133(18):1946-50. PubMed ID: 24084971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving treatment paradigm in myelofibrosis.
    Mesa RA
    Leuk Lymphoma; 2013 Feb; 54(2):242-51. PubMed ID: 22793267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
    Deininger M; Radich J; Burn TC; Huber R; Paranagama D; Verstovsek S
    Blood; 2015 Sep; 126(13):1551-4. PubMed ID: 26228487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
    Jaekel N; Behre G; Behning A; Wickenhauser C; Lange T; Niederwieser D; Al-Ali HK
    Bone Marrow Transplant; 2014 Feb; 49(2):179-84. PubMed ID: 24292520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis.
    Wang Z; Jin X; Zeng J; Xiong Z; Chen X
    Ann Hematol; 2024 Sep; 103(9):3293-3301. PubMed ID: 38494551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic approaches in myelofibrosis.
    Barosi G; Rosti V; Vannucchi AM
    Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2 inhibitors: A reality? A hope?
    Apostolidou E; Kantarjian HM; Verstovsek S
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S340-5. PubMed ID: 19778862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breakthroughs in myeloproliferative neoplasms.
    Santos FP; Verstovsek S
    Hematology; 2012 Apr; 17 Suppl 1():S55-8. PubMed ID: 22507780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
    Sastow D; Mascarenhas J; Tremblay D
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
    Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
    Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New approaches to tackle cytopenic myelofibrosis.
    Reynolds SB; Pettit K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
    Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
    Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.